Lexicon Pharmaceuticals Resubmits NDA For Sotagliflozin As Adjunct To Insulin Therapy For Glycemic Control In Type 1 Diabetes And Chronic Kidney Disease; Expects Six-Month Review And Potential Early 2025 Launch
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals has resubmitted its New Drug Application (NDA) for Sotagliflozin, intended as an adjunct to insulin therapy for glycemic control in Type 1 diabetes and chronic kidney disease. The company expects a six-month review period and a potential early 2025 launch.
June 21, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexicon Pharmaceuticals has resubmitted its NDA for Sotagliflozin, targeting Type 1 diabetes and chronic kidney disease. The review is expected to take six months, with a potential launch in early 2025.
The resubmission of the NDA for Sotagliflozin is a significant step for Lexicon Pharmaceuticals. If approved, the drug could address unmet needs in Type 1 diabetes and chronic kidney disease, potentially boosting the company's revenue and stock price. The six-month review period and early 2025 launch timeline provide a clear path forward.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100